The ORR and DOR observed in the HCC cohort of the current study are lower than those previously reported with the anti-PD-1 monoclonal antibody nivolumab given as monotherapy to patients who previously received sorafenib (12%; 9.9 months),16 showing no synergistic activity of PD-L1/CD38 combination blockade. Here, CD38 is linked to hepatocellular carcinoma.